Ian R. Hardcastle

4.2k citations

81 papers · 3.1k indexed · h-index 31

Co-authors: Bernard T. Golding Roger J. Griffin Caroline J. Richardson Graeme C.M. Smith Laurent Rigoreau David R. Newell Nicola J. Curtin Céline Cano
Topics: Cancer-related Molecular Pathways (23 papers)Bioactive Compounds and Antitumor Agents (15 papers)Cancer therapeutics and mechanisms (13 papers)
Cited by: Toxicology Organic Chemistry Oncology
Journals: Journal of the American Chemical Society PLoS ONE Cancer Research
Partner nations: United Kingdom United States Australia

In The Last Decade

Ian R. Hardcastle

81 papers receiving 3.0k citations

Peers

Countries citing papers authored by Ian R. Hardcastle

Since Specialization

Citations

This map shows the geographic impact of Ian R. Hardcastle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian R. Hardcastle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian R. Hardcastle more than expected).

Fields of papers citing papers by Ian R. Hardcastle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian R. Hardcastle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian R. Hardcastle. The network helps show where Ian R. Hardcastle may publish in the future.

Co-authorship network of co-authors of Ian R. Hardcastle

This figure shows the co-authorship network connecting the top 25 collaborators of Ian R. Hardcastle. A scholar is included among the top collaborators of Ian R. Hardcastle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian R. Hardcastle. Ian R. Hardcastle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase 2020 ·RSC Medicinal Chemistry ·Christopher J. Matheson,Christopher R. Coxon,Richard Bayliss,Kathy Boxall,Benoît Carbain,Andrew M. Fry,Ian R. Hardcastle,Suzannah J. Harnor,Corine Mas-Droux,David R. Newell,Mark W. Richards,(unknown),David M. Turner,Roger J. Griffin,Bernard T. Golding,Céline Cano	14
2	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach 2018 ·Organic & Biomolecular Chemistry ·Duncan C. Miller,Mathew P. Martin,Santosh Adhikari,(unknown),Jane Endicott,Bernard T. Golding,Ian R. Hardcastle,(unknown),(unknown),Claire Jennings,(unknown),(unknown),Stephen R. Wedge,M.E.M. Noble,Céline Cano	12
3	Structure-guided design of purine-based probes for selective Nek2 inhibition 2016 ·Oncotarget ·Christopher R. Coxon,Christopher Wong,Richard Bayliss,Kathy Boxall,(unknown),Andrew M. Fry,Ian R. Hardcastle,Christopher J. Matheson,David R. Newell,(unknown),Huw D. Thomas,David M. Turner,Sharon Yeoh,Lan Z. Wang,Roger J. Griffin,Bernard T. Golding,Céline Cano	12
4	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer 2016 ·British Journal of Cancer ·Gary Beale,Emma J. Haagensen,Huw D. Thomas,Lan-Zhen Wang,Charlotte Revill,(unknown),Bernard T. Golding,Ian R. Hardcastle,David R. Newell,Roger J. Griffin,Céline Cano	45
5	Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles 2013 ·Organic & Biomolecular Chemistry ·Honorine Lebraud,Christopher R. Coxon,(unknown),(unknown),Benoît Carbain,Christopher J. Matheson,David M. Turner,Céline Cano,Roger J. Griffin,Ian R. Hardcastle,U. Baisch,Ross W. Harrington,Bernard T. Golding	21
6	Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions 2013 ·MedChemComm ·(unknown),Shafiq U. Ahmed,Christopher R. Coxon,Junfeng Liu,Xiaohong Lü,Bernard T. Golding,Roger J. Griffin,Claire Hutton,David R. Newell,O. Stephen Ojo,Anna Watson,(unknown),Yan Zhao,John Lunec,Ian R. Hardcastle	19
7	Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy 2011 ·Chemical Biology & Drug Design ·Christiane Riedinger,M.E.M. Noble,David J. Wright,Florian F. Mulks,Ian R. Hardcastle,Jane Endicott,James M. McDonnell	12
8	Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK) 2010 ·Organic & Biomolecular Chemistry ·Céline Cano,Bernard T. Golding,(unknown),Ian R. Hardcastle,Marcus Peacock,Roger J. Griffin	14
9	Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors 2010 ·Organic & Biomolecular Chemistry ·Francesco Marchetti,Céline Cano,Nicola J. Curtin,Bernard T. Golding,Roger J. Griffin,(unknown),David R. Newell,Rachel Parsons,(unknown),Lan Z. Wang,Ian R. Hardcastle	23
10	DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Julia Bárdos,M. Raymond V. Finlay,Bernard T. Golding,(unknown),Roger J. Griffin,Ian R. Hardcastle,Keith Menear,Attilla Ting,Paul Turner,(unknown),Céline Cano	18
11	Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates 2010 ·Organic & Biomolecular Chemistry ·Christopher Wong,Roger J. Griffin,Ian R. Hardcastle,Julian S. Northen,Lan-Zhen Wang,Bernard T. Golding	14
12	Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract] 2008 ·Cancer Research ·(unknown),Mark R. Albertella,Céline Cano,Nicola J. Curtin,Mark Frigerio,Bernard T. Golding,(unknown),Ian R. Hardcastle,Marc Hummersone,Keith Menear,David R. Newell,(unknown),Caroline J. Richardson,Laurent Rigoreau,(unknown),Graeme C.M. Smith,Roger J. Griffin	3
13	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) 2008 ·Bioorganic & Medicinal Chemistry Letters ·Marine Desage‐El Murr,Céline Cano,Bernard T. Golding,Ian R. Hardcastle,(unknown),Mark Frigerio,Nicola J. Curtin,Keith Menear,Caroline J. Richardson,Graeme C.M. Smith,Roger J. Griffin	18
14	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2 2007 ·Organic & Biomolecular Chemistry ·Francesco Marchetti,Kerry L. Sayle,Johanne Bentley,W. Clegg,Nicola J. Curtin,Jane Endicott,Bernard T. Golding,Roger J. Griffin,(unknown),Ross W. Harrington,Véronique Mesguiche,David R. Newell,M.E.M. Noble,Rachel Parsons,D.J. Pratt,Lan Z. Wang,Ian R. Hardcastle	15
15	Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ian R. Hardcastle,Shafiq U. Ahmed,Helen Atkins,A H Calvert,Nicola J. Curtin,Gillian Farnie,Bernard T. Golding,Roger J. Griffin,(unknown),Claire Hutton,Per Källblad,(unknown),(unknown),David R. Newell,Stefano Norbedo,Julian S. Northen,Rebecca J. Reid,(unknown),Henriëtte M. G. Willems,John Lunec	79
16	2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK) 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jonathan J. Hollick,Bernard T. Golding,Ian R. Hardcastle,Niall M.B. Martin,Caroline J. Richardson,Laurent Rigoreau,Graeme C.M. Smith,Roger J. Griffin	83
17	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor 2002 ·Nature Structural Biology ·Thomas G. Davies,Johanne Bentley,Christine E. Arris,(unknown),Nicola J. Curtin,Jane Endicott,Ashleigh E. Gibson,Bernard T. Golding,Roger J. Griffin,Ian R. Hardcastle,Philip J. Jewsbury,L.N. Johnson,Véronique Mesguiche,David R. Newell,M.E.M. Noble,Julie A. Tucker,Lan Wang,(unknown)	173
18	Solid-phase synthesis of novel inhibitors of Farnesyl Transferase 1999 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Ian R. Hardcastle,Martin Rowlands,Bernard Nutley,(unknown),Michael Jarman	17
19	Antiestrogens as calmodulin antagonists 1996 ·Current Medicinal Chemistry ·Ian R. Hardcastle,M.G. Rowlands,Michael Jarman	6
20	Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes 1996 ·Carcinogenesis ·David H. Phillips,Paul L. Carmichael,Alan Hewer,Kathleen J. Cole,Ian R. Hardcastle,Grace K. Poon,Adrian Keogh,Alastair J. Strain	63

About Ian R. Hardcastle

Ian R. Hardcastle is a scholar working on Toxicology, Organic Chemistry and Oncology, having authored 81 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (23 papers), Bioactive Compounds and Antitumor Agents (15 papers) and Cancer therapeutics and mechanisms (13 papers). The work is most often cited by research in Toxicology (149 citations), Organic Chemistry (1.1k citations) and Oncology (993 citations). Ian R. Hardcastle has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Bernard T. Golding, Roger J. Griffin, Caroline J. Richardson, Graeme C.M. Smith, Laurent Rigoreau, David R. Newell, Nicola J. Curtin, Céline Cano, Michael Jarman and Jane Endicott. Their work appears in journals such as Journal of the American Chemical Society, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact